Albireo Pharma to present findings from multiple studies on PFIC
Albireo Pharma announced that findings from multiple studies on progressive familial intrahepatic cholestasis and other cholestatic liver diseases will be presented at major upcoming North American liver meetings. Findings from two studies on cholestatic liver diseases will be presented during poster sessions at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition 2018 Annual Meeting, being held Oct. 24-27, 2018, in Hollywood, Fla. In addition, data from the NAPPED Consortium study evaluating the natural history of PFIC will be presented by an international research team at the American Association for the Study of Liver Diseases The Liver Meeting, being held Nov. 9-13, 2018, in San Francisco. At NASPGHAN, the following posters will be presented on October 26: "Symptoms and daily impacts associated with progressive familial intrahepatic cholestasis and other pediatric cholestatic liver diseases: a qualitative study with patients and caregivers," abstract number 352, and "Systematic literature review of the effect of partial external biliary diversion surgery on clinical and biochemical outcomes in progressive familial intrahepatic cholestasis patients," abstract number 353. At AASLD, the following presentations on November 11 are particularly relevant for the development of A4250: "The Natural Course of F1C1 Deficiency: Results from the NAPPED Consortium," abstract number 1847, and "The Natural Course of BSEP Deficiency: Results from the Global NAPPED Consortium," abstract number 0185. NAPPED is supported by an unrestricted grant from Albireo. Additional data on the relevance of bile acids in cholestatic liver disease will be presented elsewhere at AASLD.